| Dr Leslie Anne Lords, PHARMD | |
|
1743 Redstone Center Dr, Park City, UT 84098 | |
| (209) 468-8716 | |
| Not Available |
| Full Name | Dr Leslie Anne Lords |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1743 Redstone Center Dr, Park City, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053433482 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 36814 (California) | Secondary |
| 183500000X | Pharmacist | P3910 (Idaho) | Secondary |
| 183500000X | Pharmacist | 65711491701 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Leslie Anne Lords, PHARMD 1743 Redstone Center Dr, Park City, UT 84098-7929 Ph: (209) 468-8716 | Dr Leslie Anne Lords, PHARMD 1743 Redstone Center Dr, Park City, UT 84098 Ph: (209) 468-8716 |
News Archive
Glioblastoma, the most widespread and lethal primary brain tumor in adults, is notoriously difficult to treat due to the surrounding lack of oxygen essential to the effectiveness of current treatment.
Research led by David Worthylake, PhD, Assistant Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, may help lay the groundwork for the development of a compound to prevent the spread of cancer. The research will be published in the May 29, 2009 issue of the Journal of Biological Chemistry.
Administration officials will "try to encourage reluctant states" to move forward with health exchanges, even as time appears to be running out, Reuters reports. Also in the news, consumer representatives from the National Association of Insurance Commissioners offered state and federal officials suggestions about how they should write regulations to implement the health law's key consumer protections.
Pharmasset, Inc. today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy.
Scientists at the Universities of Heidelberg and Ulm and a unit of the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, have discovered that a specific signal within brain cells may determine whether they live or die after a stroke.
› Verified 5 days ago
Dr. Erin Gurney, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 750 Round Valley Dr Ste 201, Park City, UT 84060 Phone: 435-649-7680 Fax: 435-776-9353 | |
Heath Lamoreaux, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6545 N Landmark Dr, Park City, UT 84098 Phone: 435-647-9050 Fax: 435-647-9042 | |
Dr. Stephanie Croteau, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1441 Ute Blvd Ste 370, Park City, UT 84098 Phone: 307-840-9834 | |
Leslie Clark Crabb, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 950 Iron Horse Dr, Park City, UT 84060 Phone: 435-649-9621 | |
Joseph Tooley Jr., PHARMD, MBA Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9190 Upper Lando Ln, Park City, UT 84098 Phone: 801-821-7269 | |
Mrs. Susan Lawrence, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6545 N Landmark Dr., Park City, UT 84098 Phone: 435-647-9040 Fax: 435-647-9042 |